Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 1Myeloproliferative Disorders 1

Interventions

fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Whole-Body Irradiation 4Tacrolimus 3Mycophenolic Acid 3Cyclosporine 3Cyclophosphamide 3Pentetic Acid 2Methotrexate 2Decitabine 2Cyclosporins 2Cord Blood Stem Cell Transplantation 2Busulfan 2spartalizumab 1sabatolimab 1merphos 1ivosidenib 1fludarabine 1fedratinib 1ethanolamine oleate 1enasidenib 1decitabine and cedazuridine drug combination 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Transplantation 1Therapeutics 1Sulfamethoxazole 1Sodium Chloride 1Saline Solution, Hypertonic 1Saline Solution 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Myeloproliferative Disorders × Captopril × Clear all
NCT04629651 2023-10-11

Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms

Case Comprehensive Cancer Center

Phase 1/2 Withdrawn
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡